Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02116803
Title An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | ESP | DNK | BEL | AUT

Facility Status City State Zip Country Details
Novartis Investigative Site Las Vegas Nevada 89169 United States Details
Novartis Investigative Site Bronx New York 10467-2490 United States Details
Novartis Investigative Site Salzburg 5020 Austria Details
Novartis Investigative Site Wilrijk 2610 Belgium Details
Novartis Investigative Site Copenhagen DK-2100 Denmark Details
Novartis Investigative Site Pavia PV 27100 Italy Details
Novartis Investigative Site Torino TO 10153 Italy Details
Novartis Investigative Site Osaka-city Osaka 545-8586 Japan Details
Novartis Investigative Site Palma De Mallorca Islas Baleares 07120 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field